Photodynamic therapy for choroidal neovascularization in young adult patients
- PMID: 20127140
- DOI: 10.1007/s10792-010-9346-3
Photodynamic therapy for choroidal neovascularization in young adult patients
Abstract
We report our experience with photodynamic therapy (PDT) in the treatment of choroidal neovascularization (CNV) in young adult patients. This was a retrospective study of young adults with CNV treated with PDT. Data collected included age, diagnosis, type and size of CNV, number of treatments, visual outcome, and side effects. Ten patients (11 eyes) were included in the study (mean age 27.2 +/- 13.3 years). Etiologies included multifocal choroiditis (3 eyes), idiopathic CNV (5 eyes), central serous chorioretinopathy (1 eye), and toxoplasma (2 eye). The mean number of treatments was 2 +/- 0.7 and the mean follow-up time was 13.1 +/- 9.5 months. Initial visual acuity (VA) ranged from 20/25 to 20/1,200 (mean logMAR 0.6 +/- 0.5), and improved to 20/20 to 20/250 (mean logMAR 0.46 +/- 0.4) (P = 0.51). Of the four eyes that received additional treatment with oral steroids, one of which also received intravitreal bevacizumab (Avastin) injections, all had visual acuity improvement of 2 or more lines, while only two of seven eyes that received PDT alone showed such improvement. PDT can improve visual outcome in a subgroup of young patients with subfoveal CNV especially when supplemented with oral steroid and bevacizumab injections.
Similar articles
-
Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis.Arch Ophthalmol. 2010 Sep;128(9):1100-3. doi: 10.1001/archophthalmol.2010.205. Arch Ophthalmol. 2010. PMID: 20837791 Clinical Trial.
-
ANTIANGIOGENICS IN CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH LASER IN CENTRAL SEROUS CHORIORETINOPATHY.Retina. 2016 May;36(5):901-8. doi: 10.1097/IAE.0000000000000804. Retina. 2016. PMID: 27115855
-
Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration.Retina. 2008 May;28(5):675-81. doi: 10.1097/IAE.0b013e31816b316e. Retina. 2008. PMID: 18463509
-
Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation.Br J Ophthalmol. 2010 Jul;94(7):864-70. doi: 10.1136/bjo.2009.166025. Epub 2009 Dec 3. Br J Ophthalmol. 2010. PMID: 19965833 Review.
-
[Secondary choroidal neovascularization-Really so common?].Ophthalmologie. 2025 Mar;122(3):196-200. doi: 10.1007/s00347-025-02197-8. Epub 2025 Feb 10. Ophthalmologie. 2025. PMID: 39928089 Review. German.
Cited by
-
Intravitreal bevacizumab as a primary treatment for idiopathic choroidal neovascularization.Middle East Afr J Ophthalmol. 2011 Jul;18(3):220-3. doi: 10.4103/0974-9233.84051. Middle East Afr J Ophthalmol. 2011. PMID: 21887077 Free PMC article.
-
Management of uveitis-related choroidal neovascularization: from the pathogenesis to the therapy.J Ophthalmol. 2014;2014:450428. doi: 10.1155/2014/450428. Epub 2014 Apr 27. J Ophthalmol. 2014. PMID: 24868454 Free PMC article. Review.
-
High‑dose aflibercept injection has striking effects on myopic choroidal neovascularization.Exp Ther Med. 2023 May 9;25(6):301. doi: 10.3892/etm.2023.12000. eCollection 2023 Jun. Exp Ther Med. 2023. PMID: 37229317 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources